Cambridge Antibody Technology

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Retrieved on: 
Tuesday, November 14, 2023
HM, Albireo, Therapy, Notifiable disease, Biotechnology, LSE, Arrow, Cambridge Antibody Technology, Science, CAT, London Stock Exchange, Cellular senescence, RNA, OBE, Pharmaceutical industry, Management

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Key Points: 
  • SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman
    Exeter, UK — 14 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board.
  • Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei.
  • Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA.
  • I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”

Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi

Retrieved on: 
Monday, April 17, 2023
Antigen, Francis Crick Institute, MYC, POC, Cambridge Antibody Technology, AACR, NMT, Cleavage, Unfolded protein response, HER2, Trastuzumab, Cancer, AACR2, Trastuzumab deruxtecan, Gold, Mab, UPR, Biology, ADC, Growth, Spacecraft, Imperial College London, Breast cancer, GC, Stomach, Phenotype, Fine chemical, Pharmaceutical industry, Medical imaging, Vaccine, Mobile phone

NMT inhibitors (NMTi) have previously been shown to inhibit viability and growth of haematological cancers.

Key Points: 
  • NMT inhibitors (NMTi) have previously been shown to inhibit viability and growth of haematological cancers.
  • Myricx has also developed a transcriptional signature which predicts cancer cell sensitivity to NMTi with high confidence.
  • Myricx’s advanced chemistry offers the potential for the development of NMTi as a novel payload on a wide range of existing linker and antibody ADC technologies.
  • Myricx’s most advanced ADC, MYX2449, is a selective and ultrapotent NMTi conjugated via a cleavable linker to trastuzumab (HER2+ mAb).

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, May 10, 2022
Janus, MK2, Central nervous system, COVID-19, Neurodegeneration, Drug development, AD, Private Securities Litigation Reform Act, Eli Lilly and Company, Microglia, IND, U.S. Securities and Exchange Commission, NASDAQ, Pharmacokinetics, GLOBE, CNS, Company, Safety, Research, Janssen Pharmaceuticals, Translation, Hidradenitis suppurativa, Patient, Atopic dermatitis, Survival, Horizon Therapeutics, Cambridge Antibody Technology, Inflammatory bowel disease, Psoriatic arthritis, Risk, Annual report, MedImmune, R, Methotrexate, Drug, RA, Sale, ACRS, JAK, Psoriasis, Therapy, G&A, HS, SAD, Rheumatoid arthritis, Technology, CEO, Horizon, ATM, ITJ, Pharmaceutical industry, Food delivery, Video game

WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update.
  • Additionally, in April 2022, Aclaris sold approximately 4.8 million shares under its ATM facility for aggregate net proceeds of $73 million.
  • Net loss was $18.8 million for the first quarter of 2022 compared to $28.8 million for the first quarter of 2021.
  • Total revenue was $1.5 million for the first quarter of 2022 compared to $1.8 million for the first quarter of 2021.

Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Retrieved on: 
Thursday, September 23, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Publication, Bayer, Biotechnology, Global, Ferring Pharmaceuticals, Oncology, Protein engineering, SAB, Patient, United States Air Force Scientific Advisory Board, Molecular Partners, Technology, LinkedIn, Cambridge Antibody Technology, Bristol Myers Squibb, Monoclonal antibody, Board, Toxicity, Regeneron Pharmaceuticals, Twitter, Lymphoma, Merck, Hematology, CEO, University, Control, ADC, Genetics, Seagen, Doctor of Philosophy, MedImmune, Vaccine, Pharmaceutical industry, Fine chemical

Tubulis today announced the formation of a Scientific Advisory Board (SAB) with the appointment of international industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and hematology.

Key Points: 
  • Tubulis today announced the formation of a Scientific Advisory Board (SAB) with the appointment of international industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and hematology.
  • Attracting these accomplished and highly regarded experts as inaugural members of our Scientific Advisory Board is a validation for our technological approach and maturation as a company, said Dr. Dominik Schumacher, CEO and co-founder of Tubulis.
  • Their combined expertise in oncology research, the ADC space and bringing novel, promising therapeutic approaches through clinical development, will be of great value.
  • Over the past 12 months, Dominik and his team have secured the financing, partnerships and team of experts that will enable the company to advance their unique ADC technology platforms toward clinical proof-of-concept, added Pamela Trail, PhD, Chairwoman of Tubulis Scientific Advisory Board.

ValenzaBio Appoints Biotech Veteran Gregory Keenan, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 1, 2021
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Companies, AstraZeneca, Medical research, Södertälje Municipality, Life sciences, Cambridge Antibody Technology

In addition, Mike Solomon, Ph.D., chief executive officer of Ribometrix, has joined ValenzaBio's board of directors.

Key Points: 
  • In addition, Mike Solomon, Ph.D., chief executive officer of Ribometrix, has joined ValenzaBio's board of directors.
  • He joins ValenzaBio from Avrobio, Inc., where he served as senior vice president, global head of medical and drug safety.
  • Previously he served as vice president, U.S., medical affairs and head medical officer at AstraZeneca, which he joined following the companys acquisition of Medimmune, where he was senior vice president, medical affairs.
  • Previously, he was chief operating officer at Ember Therapeutics, a Third Rock company, and earlier, was chief business officer at Link Medicine, which was acquired by AstraZeneca in 2012.

AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment

Retrieved on: 
Monday, December 14, 2020
Technology, Research, Biotechnology, Networks, Health, Pharmaceutical, General Health, Other Science, Science, Medical specialties, Immunology, Medicine, Clinical medicine, Monoclonal antibody, Antibody, Antibody Solutions, Cambridge Antibody Technology, AlivaMab Discovery Services (ADS), Alivalign, AlivaMab Mouse and Ablexis, LLC

AlivaMab Discovery Services, ("ADS") a leader in discovery of superior antibody therapeutics, announced the expansion of its integrated platform, which now features capabilities to assess the developability of antibody therapeutics.

Key Points: 
  • AlivaMab Discovery Services, ("ADS") a leader in discovery of superior antibody therapeutics, announced the expansion of its integrated platform, which now features capabilities to assess the developability of antibody therapeutics.
  • By providing fully human lead antibodies and backups that are characterized for developability, including specificity, stability, expression, and manufacturability, ADS provides a fully integrated approach in lead selection," said John Lippy Lippincott, PhD, Vice-President of Research of AlivaMab Discovery Services.
  • AlivaMab Discovery Services is a privately held technology company with an integrated therapeutic antibody discovery platform that combines innovative technologies and deep expertise to deliver superior antibody drug candidates in rapid timelines.
  • About AlivaMab Mouse and Ablexis, LLC
    Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery.

XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy

Retrieved on: 
Wednesday, July 22, 2020
Health sciences, Health, Immunology, Life sciences, Antibody, Glycoproteins, Therapy, Humanized antibody, Cambridge Antibody Technology

We believe that the new molecule has the potential to be another blockbuster therapeutic with proven industry appeal.

Key Points: 
  • We believe that the new molecule has the potential to be another blockbuster therapeutic with proven industry appeal.
  • This discovery points to a potential blockbuster therapy for the Companys new anti-IL-1 antibody product line.
  • XBiotech currently is advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases.
  • The sale of the antibody generated $750 million in upfront cash and up to $600 million in potential milestone payments.

CytomX Therapeutics Announces New Employment Inducement Grant

Retrieved on: 
Friday, February 7, 2020
Companies, Life sciences, Biotechnology, Monoclonal antibodies, Monoclonal antibody therapy, Amgen, AbbVie Inc., Bristol-Myers Squibb, Cambridge Antibody Technology, Celgene

The performance option vests upon the accomplishment of certain clinical trial related goals established by the Company.

Key Points: 
  • The performance option vests upon the accomplishment of certain clinical trial related goals established by the Company.
  • CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.
  • In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen and Bristol-Myers Squibb Company.
  • PROBODY is a registered trademark of CytomX Therapeutics.

BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio

Retrieved on: 
Wednesday, May 8, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Oncology, Pharmaceutical, Research, Science, Medical specialties, Life sciences, Immunology, Medicine, Genmab, MAbs, Monoclonal antibodies, Trubion, Cambridge Antibody Technology

Under the terms of the agreement, BioNTech has acquired MabVax Therapeutics lead candidate, MVT-5873, as well as other pre-clinical antibody assets to expand and complement its existing antibody portfolio and proprietary RiboMABS development capabilities.

Key Points: 
  • Under the terms of the agreement, BioNTech has acquired MabVax Therapeutics lead candidate, MVT-5873, as well as other pre-clinical antibody assets to expand and complement its existing antibody portfolio and proprietary RiboMABS development capabilities.
  • MabVax Therapeutics has developed an antibody with a novel mode of action in a disease indication that complements our pipeline expansion plans.
  • This clinical-stage antibody together with the other pre-clinical assets that we have acquired from MabVax Therapeutics enhance our antibody portfolio, which also benefits from our ongoing collaboration with Genmab and the acquisition of MAB Discovery earlier this year.
  • In conjunction with the agreement, BioNTech has purchased MabVax Therapeutics infrastructure and laboratory equipment with the intention of establishing a research facility in San Diego.

Avillion Appoints Dr David Chiswell OBE as Board Member

Retrieved on: 
Thursday, March 14, 2019
AstraZeneca, Cambridge Antibody Technology, Abingworth, Chiswell

Avillion LLP's CEO, Dr Allison Jeynes commented: "We are delighted with David's appointment.

Key Points: 
  • Avillion LLP's CEO, Dr Allison Jeynes commented: "We are delighted with David's appointment.
  • Dr Chiswell has over 30 years' experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002.
  • Dr Chiswell will join Kurt Wheeler (Blackstone), Jim Reddoch (Royalty Pharma), Genghis Lloyd-Harris (Abingworth) and Ted Love (Independent) as a Non-Executive Director on the Board of Directors of Bond 2 Development 2 GP Limited.
  • With an agnostic approach to therapy area, Avillion prides itself in adding value around operational expertise while being backed by established long-term investors.